ArticlePharmaceutical nanotechnology2025

Nanotechnology Platform for the Delivery of Docetaxel and Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer Therapy.

Bharathi Mandala et al.PubMed ↗Publisher ↗

No numbers read from the abstract.